Progenics Pharmaceuticals has selected Curium to be the distributor of its PSMA-targeted small molecule PET/CT imaging agent, PyL, in Europe.
The oncology company has granted an exclusive license to Curium to develop, and oversee regulatory approval and commercialization of the tracer, which is currently in Phase 3 development and designed to visualize prostate cancer.
“Curium is a world-class leader in nuclear medicine and an ideal partner for PyL, with the infrastructure, commercial footprint and experience in prostate cancer to position PyL for success in Europe,” Mark Baker, CEO of Progenics, said in a statement. “This collaboration accelerates development of PyL in this important market, while we focus our internal efforts on advancing our Phase 3 CONDOR trial and laying the groundwork for commercialization in the United States.”
A nuclear medicine manufacturer, Curium recently partnered with RadioMedix
to develop and commercialize 64Cu-Dotatate, a tracer with a 12-hour half-life that can be used to identify suspected neuroendocrine tumors during PET exams.
It also expanded its European footprint to 25 sites back in May with the acquisition of PET diagnostics maker, Cyclopharma
. The move expanded its French network to 13 radiopharmacies.
The addition of the distribution rights for PyL to the Curium portfolio is a classic example of its initiative to continue growing and expanding its portfolio of nuclear medicine diagnostics, according to Curium CEO Renaud Dehareng.
“PyL has the potential to detect small lesions, offering significant advantages over existing products and others in development,” he said. “We look forward to leveraging our success with F-Choline in prostate cancer to advance the development and commercial uptake of this next-generation product.”
Curium is set to meet with European regulators in the first half of 2019 to determine an agreed-upon regulatory path.
Progenics is entitled to royalties on net sales.